Are we in the beginning stages of divorce proceedings from our love affair with the environment?

Mark Viner, MD, shares his thoughts on the place cannabis holds in psychiatry and addressing the stigma cannabis faces.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

In the psychiatric care continuum, insurance companies encourage a broader conversation about what constitutes best treatment practices.

Wilsa Charles Malveaux, MD, MA, FAPA, explores the intersection of mental health and sports, using innovative technology to enhance athlete performance and well-being.

The new child and adolescent section editor for Psychiatric Times offers his thoughts on how best to engage with youth patients.

Explore the challenges of adolescent mental health and the impact of stigma.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Judith S. Beck, PhD, and Janeé M. Steele, PhD, engage in a conversation about how clinicians from all backgrounds can address issues of race in session and also empower Black patients with a sense of personal pride in their identities.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

As cannabis transitions from an illicit drug to a multi-billion-dollar industry, psychiatry faces both challenges and opportunities in exploring its therapeutic potential while balancing the risks.

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

What are the current, emerging mental health concerns?

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

Psychiatric Times spoke with Altha Stewart, MD, to discuss Black history in mental health care and strides the psychiatric community is making to ensure a more inclusive future.

Let's reflect on managed care as we celebrate the 40th anniversary of Psychiatric Times.

Mena Mirhom, MD, FAPA, introduces his new column focused on mastering media as a mental health clinician.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

"She walks in beauty, like the night, Of cloudless climes and starry skies; And all that’s best of dark and bright, Meet in her aspect and her eyes..."

Today, let’s be loving to the environment and each other.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how optimizing SSRI dosage, potentially augmenting with another medication class, and intensifying psychosocial support helps address breakthrough PPD symptoms in mothers with partial response to current SSRI treatment.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.